Pipeline

Overview 2018-04-13T17:46:02+00:00

Therapeutic Area

Drug/ Target

Indication
Preclinical
Phase I
Phase II
Phase III

Anticipated Milestones

Anticipated Milestones

Complete enrollment mid 2018

Patient enrollment ongoing

Initiate clinical studies by end of 2018

Anticipated Milestones

Launched studies for Primary FSGS: non-nephrotic and nephrotic syndrome

Vifor has future option

Anticipated Milestones

Explore Partnering Options to Advance Program in IBD

Progress in TH17 Disease

Drug: Indication (Target)
Pre
PI
PII
PIII
Anticipated Milestones

Advance CCX872 in combination with other therapies